#1 Clinical Trials Search in Europe

Sar-443579

SAR443579 is an investigational drug currently being studied in clinical trials for various blood cancers, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), high-risk myelodysplastic syndrome (HR-MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). This article provides an overview of the ongoing research and potential benefits of SAR443579 for patients with these challenging conditions.

Table of Contents

What is SAR443579?

SAR443579 is an investigational drug currently being studied for the treatment of certain blood cancers[1]. It is a new medication that is still in the early stages of research, specifically in what’s called a “first-in-human” study. This means it’s the first time the drug is being tested in people after initial laboratory research[1].

What conditions does SAR443579 treat?

SAR443579 is being investigated to treat several types of blood cancers and related conditions[1]:

  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, causing rapid growth of abnormal white blood cells.
  • B-cell Acute Lymphoblastic Leukemia (B-ALL): A cancer of the blood and bone marrow that affects B lymphocytes, a type of white blood cell.
  • High-Risk Myelodysplastic Syndrome (HR-MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells.
  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A rare and aggressive type of blood cancer that affects a specific type of immune cells.

The drug is being studied in patients whose cancer has either come back after treatment (relapsed) or hasn’t responded well to previous treatments (refractory)[1].

How does SAR443579 work?

SAR443579 is designed to target a specific protein called CD123, which is found on the surface of certain cancer cells[1]. While the exact mechanism isn’t fully described in the available information, drugs that target CD123 typically work by helping the immune system recognize and attack cancer cells more effectively.

Current Clinical Trial

SAR443579 is currently being studied in a clinical trial. This trial is an “open-label, first-in-human, dose-escalation/expansion study”[1]. Here’s what these terms mean:

  • Open-label: Both the researchers and participants know which treatment is being given.
  • First-in-human: This is the first time the drug is being tested in people.
  • Dose-escalation: The study will test different doses of the drug to find the safest and most effective dose.
  • Expansion: Once a safe dose is found, more participants will be added to further study the drug’s effects.

Who can participate in the trial?

The trial is open to both adults and children with specific blood cancers[1]. Key eligibility criteria include:

  • Age: Participants must be at least 1 year old. Adults are defined as 12 years and older, while the pediatric arm includes ages 1 to 17.
  • Diagnosis: Participants must have one of the blood cancers mentioned earlier (AML, B-ALL, HR-MDS, or BPDCN).
  • Previous treatments: The cancer must have either relapsed or not responded well to previous treatments.
  • Weight: Participants must weigh at least 10 kg (about 22 pounds).

There are also several factors that might prevent someone from participating, such as certain medical conditions or previous treatments[1].

What are the objectives of the trial?

The main goals of this clinical trial are[1]:

  1. To determine the safest and most effective dose of SAR443579.
  2. To assess how well SAR443579 works against these blood cancers, particularly in patients with AML.
  3. To study how the drug behaves in the body (its pharmacokinetics).
  4. To evaluate the safety and side effects of the drug.
  5. To see if the body develops antibodies against the drug (immunogenicity).

Safety Considerations

As with any investigational drug, there may be unknown risks and side effects. The trial is designed with several safety measures in place[1]:

  • Careful monitoring of participants for any side effects or adverse reactions.
  • Regular check-ups and tests to assess the participant’s health status.
  • A process to determine the safest dose of the drug before giving it to more participants.

It’s important to note that this is an early-stage trial, and much is still unknown about SAR443579. Patients considering participation should discuss the potential risks and benefits thoroughly with their healthcare provider and the research team.

Aspect Details
Drug Name SAR443579
Administration Intravenous infusion
Target Conditions Relapsed/refractory AML, B-ALL, HR-MDS, BPDCN
Study Population Adults and children (1+ years old)
Primary Objectives Determine MTD/MAD, assess anti-leukemic activity
Secondary Objectives Safety profile, PK profile, immunogenicity, response rates
Key Inclusion Criteria Specific diagnoses, relapsed/refractory disease, no available therapies
Key Exclusion Criteria Certain medical conditions, recent transplants, pregnancy
Primary Endpoints Incidence of DLTs, proportion of CR+CRi
Secondary Endpoints RDE, adverse events, PK parameters, ADA incidence, response rates

FAQ

  • What is SAR443579? SAR443579 is an investigational drug being studied for the treatment of certain blood cancers. It is administered through intravenous infusion and targets a specific protein called CD123, which is found on the surface of some cancer cells.
  • What types of blood cancers is SAR443579 being tested for? SAR443579 is being studied in clinical trials for relapsed or refractory acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), high-risk myelodysplastic syndrome (HR-MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  • Who can participate in the clinical trials for SAR443579? The clinical trials are open to both adults and children (at least 1 year old) with specific blood cancers. Eligibility criteria include having relapsed or refractory disease and no available therapies with known clinical benefit. Detailed criteria are set for each type of cancer and age group.
  • What are the main goals of the SAR443579 clinical trials? The main objectives of the trials are to determine the safe and effective dose of SAR443579, assess its anti-leukemic activity, evaluate its safety and tolerability, and study how the drug behaves in the body (pharmacokinetics).
  • Are there any specific exclusions for participating in the SAR443579 trials? Yes, there are several exclusion criteria. These include having certain medical conditions, recent or ongoing other cancers, active central nervous system leukemia, HIV/AIDS, active hepatitis B or C, or recent stem cell transplants. Pregnant and breastfeeding women are also excluded.

Ongoing Clinical Trials on Sar-443579

  • Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands

Glossary

  • Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow and quickly moves into the blood, affecting the production of normal blood cells.
  • B-cell Acute Lymphoblastic Leukemia (B-ALL): A fast-growing cancer of the white blood cells, specifically affecting B-lymphocytes, which are important for fighting infections.
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells. High-risk MDS has a higher chance of progressing to leukemia.
  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A rare and aggressive type of blood cancer that affects a specific type of immune cells called plasmacytoid dendritic cells.
  • Relapsed: When cancer returns after a period of improvement or remission following treatment.
  • Refractory: When cancer does not respond to treatment or stops responding after initial improvement.
  • Complete Remission (CR): When there are no detectable cancer cells in the body after treatment.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent increasing the dose or continuing treatment.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Anti-Drug Antibody (ADA): Antibodies produced by the body's immune system against a therapeutic drug, which can affect the drug's effectiveness or safety.
  • Hematopoietic Stem Cell Transplantation (HSCT): A procedure that replaces damaged or diseased bone marrow with healthy blood-forming stem cells.

References

  1. http://clinicaltrials.eu/trial/study-of-sar443579-infusion-for-adults-and-children-with-relapsed-or-refractory-acute-myeloid-leukemia-b-cell-acute-lymphoblastic-leukemia-hr-mds-or-bpdcn/